Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q3 2023 · 10-Q
Revenue$136.71M$136.71M+7.6% vs Q3 2022 Net Income$20.63M$20.63M+4,415.1% vs Q3 2022 EPS Diluted$0.53$0.53+5,200.0% vs Q3 2022 Gross Profit$80,311,000+36.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flowderived$74,018,000+73.1% Free Cash Flowderived$73,953,000+73.4% Margins · derivedGross margin58.7%+12.4 pt vs Q3 2022
Operating margin32.9%+16.8 pt vs Q3 2022
Net margin15.1%+14.7 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 7, 2023 · 38 d after period end